scholarly journals Is there a role for upper-extremity intra-aortic balloon counterpulsation as a bridge-to-recovery or a bridge-to-transplant in the treatment of end-stage heart failure?

2017 ◽  
Vol 25 (4) ◽  
pp. 654-658 ◽  
Author(s):  
Nnamdi Nwaejike ◽  
Andre Y. Son ◽  
Carmelo A. Milano ◽  
Mani A. Daneshmand
Circulation ◽  
2007 ◽  
Vol 116 (suppl_16) ◽  
Author(s):  
Forum Kamdar ◽  
Andrew Boyle ◽  
Monica Colvin-Adams ◽  
Kenneth Liao ◽  
Lyle Joyce ◽  
...  

Introduction : Pulmonary hypertension is a frequent sequelae of end-stage heart failure and remains a contraindication for cardiac transplantation. Pulsatile LVADs have been shown to effectively reduce pulmonary hypertension in these patients. However, it remains to be seen if newer continuous flow LVADs have a similar effect on pulmonary hypertension. The objective of this study was to determine if the Heartmate (HM) II, a continuous flow LVAD is effective in improving pulmonary hemodynamics in bridge-to-transplant patients. Methods : 30 patients with end-stage heart failure underwent placement of HM II LVAD as a bridge-to-transplant (BTT) at a single center. Pulmonary hemodynamics were evaluated with right heart catheterization at baseline, after placement of an intra-aortic balloon pump (IABP), and post-LVAD (prior to heart transplant). Results : Demographic data of these patients were as follows: mean age 51.6 ± 13.3 years, 70% male, LVEF 14.7 ± 5.11%, 56.6% ischemic etiology and 83.3% received IABP prior to LVAD. Following LVAD support (mean duration of 146. 41 ± 73.83 days), systolic and diastolic pulmonary artery pressures (SPAP and DPAP) decreased significantly (SPAP 56.8 ± 13.55 mmHg, DPAP 28.27 ± 6.23 mmHg to SPAP 35.38 ± 10.23 mmHg, DPAP 15.71 ± 5.36 mmHg; p < 0.001). Similarly, pulmonary vascular resistance (PVR) decreased significantly from 3.69 ± 2.02 to 2.00 ± 0.85 Woods units (p = 0.004). Transpulmonary gradient (TPG) also declined significantly post-LVAD from 13.3 ± 5.6 to 9.35 ± 2.98 mmHg (p = 0.02). Conclusion : Continuous flow LVADs effectively improve pulmonary hemodynamics associated with end-stage heart failure. Therefore, adequate left ventricular decompression achieved with continuous flow LVAD support can reverse significant pulmonary hypertension in end-stage heart failure patients making them eligible for cardiac transplantation.


2010 ◽  
Vol 29 (12) ◽  
pp. 1427-1432 ◽  
Author(s):  
Christopher S. Hayward ◽  
William S. Peters ◽  
Alan F. Merry ◽  
Peter N. Ruygrok ◽  
Paul Jansz ◽  
...  

Author(s):  
Chi-Ming Wei ◽  
Margarita Bracamonte ◽  
Shi-Wen Jiang ◽  
Richard C. Daly ◽  
Christopher G.A. McGregor ◽  
...  

Nitric oxide (NO) is a potent endothelium-derived relaxing factor which also may modulate cardiomyocyte inotropism and growth via increasing cGMP. While endothelial nitric oxide synthase (eNOS) isoforms have been detected in non-human mammalian tissues, expression and localization of eNOS in the normal and failing human myocardium are poorly defined. Therefore, the present study was designed to investigate eNOS in human cardiac tissues in the presence and absence of congestive heart failure (CHF).Normal and failing atrial tissue were obtained from six cardiac donors and six end-stage heart failure patients undergoing primary cardiac transplantation. ENOS protein expression and localization was investigated utilizing Western blot analysis and immunohistochemical staining with the polyclonal rabbit antibody to eNOS (Transduction Laboratories, Lexington, Kentucky).


2006 ◽  
Vol 5 (1) ◽  
pp. 126-126
Author(s):  
S DRAKOS ◽  
E KALDARA ◽  
M BONIOS ◽  
D KARAGEORGOPOULOS ◽  
C PIERRAKOS ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document